Payment overview · 2025
General Payments
$418.97
16 reported records · 6 companies
Healthcare provider profile · identity verified
Peter Gerald Allegretti, M.D.
Allopathic & Osteopathic Physicians|Family Medicine · LIBERTYVILLE, IL · NPI 1720152317
Verified facts
What the public records show
CMS Open Payments records show Peter Gerald Allegretti, M.D. received $418.97 in general payments during 2025 across 16 reported records.
Novo Nordisk Inc accounted for 50.7% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 10 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Rybelsus.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 165 claims for Synthroid by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 42 claims for Jardiance by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Rybelsus as an associated drug or biological on 161257 records involving 55409 distinct recipient NPIs. Public Medicare Part D data also shows 19 claims for Rybelsus by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $212.50 | 50.7% | 6 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $83.05 | 19.8% | 4 | 2025 |
| Abbott Laboratories | Unresolved — no canonical attribution shown | $55.21 | 13.2% | 3 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $24.45 | 5.8% | 1 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $22.23 | 5.3% | 1 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $21.53 | 5.1% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $418.97 | 16 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $192.70 | 5 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $83.05 | 4 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $71.00 | 3 | 2025 |
Source payment records
|
|||||
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $63.79 | 3 | 2025 |
Source payment records
|
|||||
| FREESTYLE LIBRE 3 Normalized: freestyle libre 3 |
Device | Abbott Laboratories | $55.21 | 3 | 2025 |
Source payment records
|
|||||
| OTEZLA Normalized: otezla |
Drug | Amgen Inc. | $24.45 | 1 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $24.45 | 1 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $22.23 | 1 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $22.23 | 1 | 2025 |
Source payment records
|
|||||
| BREZTRI Normalized: breztri |
Drug | AstraZeneca Pharmaceuticals LP | $21.53 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| Rybelsus rybelsus |
2025 | Rybelsus | 2024 | 19 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
165 | 42 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
42 | 13 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Rybelsus open payments reported associated product |
CMS Open Payments — General Payments 161257 supporting records · 55409 recipient NPIs · example record 1188130076 |
Rybelsus · 2024 Exact normalized brand match · 1 Part D row |
19 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 490 | 137 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 336 | 100 |
| Levothyroxine Sodium | Levothyroxine Sodium | 316 | 86 |
| Pantoprazole Sodium | Pantoprazole Sodium | 312 | 98 |
| Amlodipine Besylate | Amlodipine Besylate | 284 | 89 |
| Metoprolol Succinate | Metoprolol Succinate | 255 | 68 |
| Furosemide | Furosemide | 217 | 63 |
| Metformin Hcl | Metformin Hcl | 201 | 59 |
| Hydrochlorothiazide | Hydrochlorothiazide | 198 | 60 |
| Tamsulosin Hcl | Tamsulosin Hcl | 180 | 50 |
| Gabapentin | Gabapentin | 179 | 45 |
| Synthroid | Levothyroxine Sodium | 165 | 42 |
| Allopurinol | Allopurinol | 144 | 41 |
| Lisinopril | Lisinopril | 139 | 46 |
| Potassium Chloride | Potassium Chloride | 126 | 41 |
| Azithromycin | Azithromycin | 119 | 87 |
| Lorazepam | Lorazepam | 95 | 18 |
| Omeprazole | Omeprazole | 95 | 24 |
| Carvedilol | Carvedilol | 88 | 27 |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 86 | 23 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 85 | 35 |
| Montelukast Sodium | Montelukast Sodium | 80 | 30 |
| Clopidogrel | Clopidogrel Bisulfate | 79 | 25 |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 77 | 22 |
| Trazodone Hcl | Trazodone Hcl | 76 | 25 |
| Sertraline Hcl | Sertraline Hcl | 74 | 21 |
| Tramadol Hcl | Tramadol Hcl | 73 | 14 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 72 | 20 |
| Simvastatin | Simvastatin | 72 | 19 |
| Metoprolol Tartrate | Metoprolol Tartrate | 70 | 23 |
| Eliquis | Apixaban | 64 | 20 |
| Atenolol | Atenolol | 56 | 15 |
| Losartan Potassium | Losartan Potassium | 54 | 19 |
| Digoxin | Digoxin | 53 | 12 |
| Prednisone | Prednisone | 52 | 27 |
| Zolpidem Tartrate | Zolpidem Tartrate | 51 | 11 |
| Glimepiride | Glimepiride | 50 | 16 |
| Methylprednisolone | Methylprednisolone | 49 | 39 |
| Ezetimibe | Ezetimibe | 46 | 16 |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 45 | 12 |
| Ramipril | Ramipril | 45 | 13 |
| Irbesartan | Irbesartan | 44 | 14 |
| Metformin Hcl Er | Metformin Hcl | 44 | 12 |
| Pravastatin Sodium | Pravastatin Sodium | 43 | 12 |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 42 | 13 |
| Jardiance | Empagliflozin | 42 | 13 |
| Lansoprazole | Lansoprazole | 40 | 12 |
| Alprazolam | Alprazolam | 39 | suppressed |
| Amoxicillin | Amoxicillin | 39 | 22 |
| Doxycycline Hyclate | Doxycycline Hyclate | 38 | 27 |
| Nebivolol Hcl | Nebivolol Hcl | 38 | 14 |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 35 | 31 |
| Spironolactone | Spironolactone | 35 | 12 |
| Donepezil Hcl | Donepezil Hcl | 34 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 30 | 24 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 30 | suppressed |
| Xarelto | Rivaroxaban | 30 | suppressed |
| Ipratropium Bromide | Ipratropium Bromide | 29 | suppressed |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 28 | 16 |
| Pregabalin | Pregabalin | 28 | suppressed |
| Memantine Hcl | Memantine Hcl | 27 | suppressed |
| Terazosin Hcl | Terazosin Hcl | 27 | suppressed |
| Celecoxib | Celecoxib | 26 | suppressed |
| Citalopram Hbr | Citalopram Hydrobromide | 26 | suppressed |
| Nifedipine Er | Nifedipine | 25 | suppressed |
| Cephalexin | Cephalexin | 24 | 15 |
| Warfarin Sodium | Warfarin Sodium | 24 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 21 | suppressed |
| Enalapril Maleate | Enalapril Maleate | 19 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 19 | suppressed |
| Midodrine Hcl | Midodrine Hcl | 19 | suppressed |
| Repatha Sureclick | Evolocumab | 19 | suppressed |
| Rybelsus | Semaglutide | 19 | suppressed |
| Clonazepam | Clonazepam | 18 | suppressed |
| Duloxetine Hcl | Duloxetine Hcl | 18 | suppressed |
| Glipizide | Glipizide | 18 | suppressed |
| Olmesartan-Hydrochlorothiazide | Olmesartan/Hydrochlorothiazide | 18 | suppressed |
| Tresiba Flextouch U-200 | Insulin Degludec | 18 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 18 | 12 |
| Azelastine Hcl | Azelastine Hcl | 17 | suppressed |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 17 | 13 |
| Ezetimibe-Simvastatin | Ezetimibe/Simvastatin | 17 | suppressed |
| Telmisartan | Telmisartan | 17 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 17 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 16 | suppressed |
| Diazepam | Diazepam | 16 | suppressed |
| Finasteride | Finasteride | 16 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 16 | suppressed |
| Meloxicam | Meloxicam | 16 | suppressed |
| Colesevelam Hcl | Colesevelam Hcl | 15 | suppressed |
| Fenofibrate | Fenofibrate,micronized | 15 | suppressed |
| Valsartan | Valsartan | 15 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 14 | suppressed |
| Insulin Lispro Kwikpen U-100 | Insulin Lispro | 14 | suppressed |
| Ketoconazole | Ketoconazole | 14 | suppressed |
| Oxybutynin Chloride | Oxybutynin Chloride | 14 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 13 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 13 | 12 |
| Fenofibrate | Fenofibrate Nanocrystallized | 13 | suppressed |
| Fluoxetine Hcl | Fluoxetine Hcl | 13 | suppressed |
| Hydralazine Hcl | Hydralazine Hcl | 13 | suppressed |
| Lovastatin | Lovastatin | 13 | suppressed |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 13 | suppressed |
| Pentoxifylline | Pentoxifylline | 13 | suppressed |
| Verapamil Er | Verapamil Hcl | 13 | suppressed |
| Diltiazem 24hr Er (Xr) | Diltiazem Hcl | 12 | suppressed |
| Escitalopram Oxalate | Escitalopram Oxalate | 12 | suppressed |
| Irbesartan-Hydrochlorothiazide | Irbesartan/Hydrochlorothiazide | 12 | suppressed |
| Phenytoin Sodium Extended | Phenytoin Sodium Extended | 12 | suppressed |
| Propranolol Hcl Er | Propranolol Hcl | 12 | suppressed |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 12 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 12 | suppressed |
| Janumet Xr | Sitagliptin Phos/Metformin Hcl | 11 | suppressed |
| Paxlovid | Nirmatrelvir/Ritonavir | 11 | 11 |
| Phenobarbital | Phenobarbital | 11 | suppressed |
| Torsemide | Torsemide | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $418.97 · 16 records | Novo Nordisk Inc | BREZTRI, FREESTYLE LIBRE 3, MOUNJARO, OTEZLA, Ozempic, QULIPTA, REPATHA, Rybelsus, UBRELVY, ZEPBOUND | 3 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Rybelsus play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error